Abstract
Purpose
ON 01910.Na is a novel targeted anti-cancer agent under clinical investigation in Phase I and II trials. The purpose of this research was to evaluate the pharmacokinetic profile of ON 01910.Na across several species, and to evaluate the effects of protein binding and duration of exposure on its in vitro cytotoxic activity.
Methods
Data were collated from several preclinical investigations, where the plasma disposition and tissue distribution of ON 01910.Na were assessed after administration (10–150 mg/kg, IP or IV) to several species (mouse, rat, and dog). Plasma protein binding was assessed using ultrafiltration. Cytotoxic activity of ON 01910.Na was determined in DU145 cells, and activity was correlated to unbound drug concentration and the duration of exposure.
Results
ON 01910.Na exhibits extensive plasma protein binding and the compound displays rapid elimination from the circulation in all three animal species (t1/2 range 0.404–0.870 h). Tissue distribution studies in mice revealed highest drug accumulation in the liver, followed by the kidneys. ON 01910.Na is not extensively metabolized in vivo and urinary excretion is predominant at higher doses. ON 01910.Na cytotoxicity in DU145 cells was adversely affected by protein binding in the incubation medium. Drug cytotoxicity was greatly enhanced upon extending the duration of exposure at reduced drug concentrations.
Conclusions
Due to the short half-life and rapid clearance of the drug, administration of ON 01910.Na by continuous IV infusion is a likely treatment option for cancer patients.
Similar content being viewed by others
References
Gumireddy K, Reddy MVR, Cosenza SC, Nathan RB, Baker SJ, Papathi N, Jiang J, Holland J, Reddy EP (2005) ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 7:275–286
Danish A, Mohan S, Sharma A, Shah A, Liu L, Alfieri A, Garg M, Kalnicki S, Reddy M, Bell S, Reddy E, Guha C (2005) Cytotoxicity and radiosensitization in cervical carcinoma cells by ON01910, a novel polo-like kinase 1 inhibitor. Int J Radiat Oncol Bio Phys 63(Suppl 1):S482–S483
Li J, Zhao M, Jimeno A, He P, Reddy MV, Hidalgo M, Donehower RC, Rudek RA (2007) Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma. J Chromatogr B 856:198–204
Jiang J, Li Y, Wang Y, Reddy E, Roboz J, Ohnumna T, Silverman L, Holland JF (2004) Anticancer effects of ON-1910Na. Proc Am Assoc Cancer Res 45:(Abstract 5382): 1241
Sumara I, Gimenez-Abian JF, Gerlich D, Hirota T, Kraft C, Torre C, Ellenberg J, Peters J (2004) Roles of polo-like kinase 1 in the assembly of functional mitotic spindles. Curr Biol 14:1712–1722
Sharma AK, Mohan S, Alfieri A, Garg M, Xi B, Cosenza S, Reddy M, Bell S, Reddy E, Guha C (2004) Radiation sensitization of prostate carcinoma cells by ONC 01910, a novel protein kinase inhibitor and cell cycle modulator. Int J Radiat Oncol Bio Phys 60(Suppl 1):S341
Mohan S, Sharma AK, Liu L, Garg M, Kalnicki S, Reddy MVR, Reddy EPK, Bell S, Alfieri AA, Guha C (2006) Inhibition of survivin phosphorylation by On01910, a novel benzylstyryl sulfone, promotes radiation sensitization in androgen independent human prostate carcinoma cells. Int J Radiat Oncol Bio Phys 66(Suppl 1):S72
Shoemaker RH (2006) The NCI60 human tumor cell line anticancer drug screen. Nat Rev Cancer 6:813–823
Screening Services: DTP Human Tumor Cell Line Screen (2008) Available via http://dtp.nci.nih.gov/branches/btb/ivclsp.html. Accessed October 1
Dutta S, Reed RC (2006) Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug: as shown by once-daily divalproex-ER. Clin Drug Investig 26:681–690
Jimeno A, Li J, Messersmith WA, Laheru D, Rudek MA, Maniar M, Hidalgo M, Baker SD, Donehower RC (2008) Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol 26:5504–5510
Acknowledgment
This research was funded by Onconova Therapeutics Inc.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chun, A.W., Cosenza, S.C., Taft, D.R. et al. Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent. Cancer Chemother Pharmacol 65, 177–186 (2009). https://doi.org/10.1007/s00280-009-1022-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-009-1022-9